Hjarta Care proactively secures patent protection for its innovations. This website provides notice to the public, including pursuant to 35 U.S.C. § 287(a), that a Hjarta Care product is patented:

FDA has granted the XplantR De Novo authorization, establishing a new device classification for aortic endograft explantation devices.

Product

Hjärta Care XplantR Explant Tool Endovascular Stent Graft Removal Tool

Patents

US 11,351,047

US 12,396,871

JP 7,814,387